Sirtex Medical and US-based Surefire Medical has announced a sales and marketing partnership to distribute Surefire’s range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.
According to a press release, the agreement will see Sirtex exclusively distribute the Surefire Medical range of products in the company’s Asia-Pacific markets including Australia.
Sirtex reported a 30% growth in dose sales of its targeted radiation treatment for liver cancer in the Asia-Pacific region at the end of the third quarter (31 March 2013).
Surefire Medical has received regulatory approval in the USA, Europe, Canada and New Zealand.
The Surefire Infusion System, according to the company, has been designed to enhance the accuracy and delivery of drugs directly to tumours. Surefire products use a patented microcatheter with an expandable tip. When deployed, the tip responds to flow conditions to enable more of the embolic agent to reach the intended destination while reducing non-target delivery compared to traditional infusion systems.
The ability to more safely and efficiently deliver embolic agents directly to target tumors marks a significant advance in radiation oncology procedures and in the treatment of liver cancer, according to the press release.
